Following FDA debacle in ’09, Motif lines up a new shot at approval for antibiotic iclaprim
Eight years after the FDA and its experts slapped down Arpida’s antibiotic iclaprim, fearful that the treatment was unsafe to use and the efficacy case …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
